Results 131 to 140 of about 8,788 (204)

Structure-Based Development of Ultra-Broad-Spectrum 3C-Like Protease Inhibitors. [PDF]

Adv Sci (Weinh)
Su H, Nie T, Chen G, Xiong M, Zhang Y, Wu G, You M, Xie H, He J, Xiong Y, Hu H, Zhao W, Li M, Xiao G, Zhang L, Xu Y.   +15 more
europepmc   +1 more source

Real-world untreated risk of hospitalization and death in a nirmatrelvir/ritonavir treatment-eligible population with mild-to-moderate COVID-19 in the United States: a systematic literature review. [PDF]

BMC Infect Dis
Migliaccio-Walle K, Mugwagwa T, Cha-Silva AS, Gong CL, Campbell D, Quercia R, Bergroth T, Veenstra DL, Moran MM, Dzingina M.   +9 more
europepmc   +1 more source

Effectiveness of nirmatrelvir/ritonavir and molnupiravir in reducing the risk of short-term and long-term cardiovascular complications of COVID-19: a target trial emulation study. [PDF]

Nat Commun
Guo Z, Wei Y, Lin G, Jia KM, Boyer C, Wang H, Li C, Hung CT, Yam CHK, Chow TY, Zhao S, Li K, Yang A, Mok CKP, Hui DS, Yeoh EK, Chong KC.   +16 more
europepmc   +1 more source

Eligibility for Nirmatrelvir/Ritonavir Among Adults With an Acute Care COVID-19 Encounter: A Retrospective Cohort Study From Alberta, Canada. [PDF]

Pharmacoepidemiol Drug Saf
Aponte-Hao S, Vu K, Randall JR, Martins KJB, Nguyen PU, Saxinger L, Leal J, Rennert-May E, Rafferty E, Williamson T, Klarenbach SW.   +10 more
europepmc   +1 more source

Insights from integrated covalent docking and molecular dynamics simulations of nirmatrelvir analogs as potential SARS-CoV-2 M^pro inhibitors. [PDF]

Sci Rep
Ibrahim MAA, Khaled DMA, Mahmoud DGM, Abdelrahman AHM, Sidhom PA, Han Y, Shoeib T, Aldahmash B, Rady A.   +8 more
europepmc   +1 more source

Nirmatrelvir/ritonavir use reduces risk for long COVID in patients with immunodeficiency. [PDF]

J Hum Immun
Gilbert KM, Aglan M, Jogdand A, Khairnar NV, Ssemaganda H, Ong MS, Farmer JR.   +6 more
europepmc   +1 more source

Successful Treatment of Multiple Myeloma Complicated With SARS-CoV-2 Infection: A Case Report. [PDF]

Case Rep Med
Meng Y, Duan B, Gao L, Huang W, Wan F.
europepmc   +1 more source

A SARS-CoV-2 M^pro mutation conferring ensitrelvir resistance paradoxically increases nirmatrelvir susceptibility. [PDF]

Nat Commun
Min SC, Seo JJ, Jeong JH, Kim BK, Park JH, Lee JR, Lee DG, Lee GC, An SH, Baek YH, Choi YK, Choo H, Park HY, Kim G, Jeon B, Shin SC, Song MS.   +16 more
europepmc   +1 more source

Impact of Single Halogen Atom Substitutions on Antiviral Profile of Inhibitors Targeting SARS-CoV‑2 Main Protease. [PDF]

ACS Omega
Bulut H, Higashi-Kuwata N, Ogata-Aoki H, Hayashi H, Takamune N, Kishimoto N, Das D, Li M, Wlodawer A, Misumi S, Tamamura H, Mitsuya H.   +11 more
europepmc   +1 more source

Regioselective multicomponent synthesis of α-boryl ureas: discovery of a potent main protease inhibitor. [PDF]

Org Biomol Chem
Gyasi YI, Nyalata S, Pa S, Gunasekera D, Vulupala VR, Mallampudi NR, Ramidi GR, Xu S.   +7 more
europepmc   +1 more source